Please assess the completion status of the following clinical trial:

Trial Title: Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have experienced a myocardial infarction (STEMI) within the previous 24 hours confirmed by symptoms and ECG.~Exclusion Criteria:~* Subjects with a known low ejection fraction of less than 40% or any previous history of heart failure.~* Subjects treated with eplerenone or other aldosterone antagonists within the past 1 month.~* The subject has uncontrolled hypotension (SBP\<90mmHg).~* Subjects with eGFR ≤30ml/min (based on admission serum creatinine and the MDRD formula) or serum creatinine ≥220µmol/L.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eplerenone plus standard of care (Type: EXPERIMENTAL): None
- Placebo plus standard of care (Type: PLACEBO_COMPARATOR): Matching placebo for eplerenone 25mg film coated tablets.

Based on this trial design, predict the completion outcome and termination type (if applicable).